The anabolic drug romosozumab (Evenity) has been recommended for PBS listing for the treatment of severe osteoporosis in patients who have experienced a prior fracture while on anti-resorptive therapy. The Pharmaceutical Benefits Advisory Committee (PBAC) made the recommendation at its March 2020 meeting, saying there is a clinical need for additional treatment options for severe ...
PBS listing recommended for romosozumab
By Michael Woodhead
28 Apr 2020